ZHANG Xiaoli 1,2,3 , ZENG Liang 1,2,3 , SHU Ruo 1,2,3 , SUN Jiaxue 1,2,3 , XIONG Pu 1,2,3 , ZHANG Zunyue 2,3,4 , LUO Huayou 1,2,3
  • 1. Department of Gastroenterology and Hernia Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032,P. R. China;
  • 2. Digestive Disease Prevention Engineering Technology Center of Yunnan Province, Kunming 650032, P. R. China;
  • 3. Yunnan Institute of Digestive Diseases, Kunming 650032, P. R. China;
  • 4. Department of Reproductive Genetics, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, P. R. China;
LUO Huayou, Email: km-lhy@qq.com
Export PDF Favorites Scan Get Citation

Objective The aim of this paper is to summarize the advantages and disadvantages of non-surgical treatments of the enterocutaneous fistula, in order to give some advice.Methods Pubmed, EMBASE, Medline, CNKI, and Wanfang databases were retrieved for the published article addressing the non-surgical treatments of enterocutaneous fistula between 2004 to 2018. The keywords were " enterocutaneous fistula” in English and Chinese, respectively. The non-surgical treatments of enterocutaneous fistula were reviewed.Results The results of this search suggested that non-surgical treatments of the enterocutaneous fistula mainly include fibrin glue, endoscopic treatment, laser ablation, and somatostatin. Fibrin glue was widely used at domestic and abroad, but it needed repeated operations. Endoscopic treatment of enterocutaneous fistula required a certain professional foundation; laser ablation technology was still immature and required theoretical data support. Now, the use of somatostatin was controversial.Conclusion Each of measures have its advantages and disadvantages, we should determine according to the patient’s condition and economic situation.

Citation: ZHANG Xiaoli, ZENG Liang, SHU Ruo, SUN Jiaxue, XIONG Pu, ZHANG Zunyue, LUO Huayou. Updates on non-surgical treatments of the enterocutaneous fistula. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(9): 1136-1140. doi: 10.7507/1007-9424.201903021 Copy

  • Previous Article

    The clinical and genetic characteristics of CDC73-associated parathyroid diseases
  • Next Article

    Predictive factors for recurrence of retroperitoneal sarcoma